Search - tctmd.com

Displaying 1 - 20 of 50

Sort: Relevancy | Date

News Conference News ACC 2025

By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE

Michael O'Riordan

March 31, 2025

News Conference News ACC 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

L.A. McKeown

March 30, 2025

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

Caitlin E. Cox

March 30, 2025

Presentation ACC 2025

Two-year Outcomes Of Transcatheter Tricuspid Valve Edge-to-Edge Repair For Tricuspid Regurgitation: The TRILUMINATE Pivotal Trial

Presenter: Saibal Kar

March 30, 2025

Presentation ACC 2025

Dapagliflozin after Transcatheter Aortic Valve Implantation

Presenter: Sergio Raposeiras-Roubin

March 29, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

Another Win for TAVI in Low-to-Intermediate Risk Patients

News Conference News ACC 2024

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

Yael L. Maxwell

April 08, 2024

News Conference News ACC 2024

TAVI, SAVR Rates Roughly Equal for Patients Younger Than 65 in New England

Yael L. Maxwell

April 05, 2024

News Conference News ACC 2023

Real-world Primary MR TEER Outcomes Carry a Reminder: Do Better

Shelley Wood

March 10, 2023

Presentation ACC 2023

Transcatheter vs Surgical Aortic Valve Replacement in Low RiskPatients: 3-Year Outcomes from the EvolutLow Risk Trial

Presenter: John K. Forrest

March 05, 2023

Presentation ACC 2023

A Landmark Randomized Clinical Trial of Transcatheter Repair for Tricuspid Regurgitation

Presenter: Paul Sorajja

March 05, 2023

Presentation ACC 2023

5-Year Follow-Up After Transcatheter Repair of Secondary Mitral Regurgitation The COAPT Trial

Presenter: Gregg W. Stone

March 05, 2023

News Conference News ACC 2023

Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients

Todd Neale

March 05, 2023

News Conference News ACC 2023

TRILUMINATE Pivotal: TEER With the TriClip Benefits Patients With Severe TR

Todd Neale

March 04, 2023

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Todd Neale

April 05, 2022

News Conference News ACC 2022

Tricuspid Repair With Pascal Safe, Effective at 1 Year: CLASP TR

Yael L. Maxwell

April 05, 2022

Presentation ACC 2022

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Presenter: Duk-Woo Park

April 04, 2022

Presentation ACC 2022

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

Presenter: Michael J. Reardon

April 04, 2022

News Conference News ACC 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Michael O'Riordan

April 04, 2022

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Shelley Wood

March 28, 2022

Advertisement

By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

Two-year Outcomes Of Transcatheter Tricuspid Valve Edge-to-Edge Repair For Tricuspid Regurgitation: The TRILUMINATE Pivotal Trial

Dapagliflozin after Transcatheter Aortic Valve Implantation

What’s Going to Be Hot at ACC 2025?

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

TAVI, SAVR Rates Roughly Equal for Patients Younger Than 65 in New England

Real-world Primary MR TEER Outcomes Carry a Reminder: Do Better

Transcatheter vs Surgical Aortic Valve Replacement in Low RiskPatients: 3-Year Outcomes from the EvolutLow Risk Trial

A Landmark Randomized Clinical Trial of Transcatheter Repair for Tricuspid Regurgitation

5-Year Follow-Up After Transcatheter Repair of Secondary Mitral Regurgitation The COAPT Trial

Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients

TRILUMINATE Pivotal: TEER With the TriClip Benefits Patients With Severe TR

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Tricuspid Repair With Pascal Safe, Effective at 1 Year: CLASP TR

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content